Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q3

4574.TEDINET S100S6X1
Period2023-01-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥4.4bn2023-01-01 → 2023-09-30Cons.Net sales
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥3.4bn2022-01-01 → 2022-09-30Cons.Net sales
Operating income−¥444m2023-01-01 → 2023-09-30Cons.Operating income
Operating income−¥2.8bn2022-01-01 → 2022-09-30Cons.Operating income
Ordinary income−¥589m2023-01-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.9bn2022-01-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥537m2023-01-01 → 2023-09-30Cons.Income before income taxes
Profit before tax−¥3.2bn2022-01-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥562m2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥562m2023-01-01 → 2023-09-30Cons.Profit loss
Net income−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss
Total assets¥15.8bnat 2023-09-30Cons.Assets
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥16.5bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥6.0bnat 2023-09-30Cons.Liabilities
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Net assets / equity¥9.8bnat 2023-09-30Cons.Net assets
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥9.8bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥4.8bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
EPS (basic)¥-12.092023-01-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-0.982023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-72.972022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.82022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio61.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-09-30−¥738m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥724m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥724m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-09-30−¥643m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2023-01-01 → 2023-09-30¥4m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2023-01-01 → 2023-09-30¥4m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2023-01-01 → 2023-09-30−¥17m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥3.7bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥3.7bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥955m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-09-30¥4.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-09-30¥4.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-09-30¥293m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥893m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.8bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2022-01-01 → 2022-09-30−¥14m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥42m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥1.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 365
ItemContextValueUnit
Accounts payable otherPrior1YearInstant554000000JPY
Accounts payable otherCurrentQuarterInstant463000000JPY
Income taxes payablePrior1YearInstant17000000JPY
Income taxes payableCurrentQuarterInstant30000000JPY
Refund liabilities clPrior1YearInstant94000000JPY
Refund liabilities clCurrentQuarterInstant58000000JPY
Provision for bonusesPrior1YearInstant23000000JPY
Provision for bonusesCurrentQuarterInstant78000000JPY
Provision for surcharge clPrior1YearInstant607000000JPY
Provision for surcharge clCurrentQuarterInstant－JPY
Asset retirement obligations clPrior1YearInstant－JPY
Asset retirement obligations clCurrentQuarterInstant196000000JPY
Other clPrior1YearInstant181000000JPY
Other clCurrentQuarterInstant425000000JPY
Current liabilitiesPrior1YearInstant2793000000JPY
Current liabilitiesCurrentQuarterInstant2778000000JPY
Long term loans payablePrior1YearInstant2720000000JPY
Long term loans payableCurrentQuarterInstant1870000000JPY
Long term accounts payable otherPrior1YearInstant549000000JPY
Long term accounts payable otherCurrentQuarterInstant549000000JPY
Net defined benefit liabilityPrior1YearInstant659000000JPY
Net defined benefit liabilityCurrentQuarterInstant612000000JPY
Asset retirement obligations nclPrior1YearInstant133000000JPY
Asset retirement obligations nclCurrentQuarterInstant4000000JPY
Other nclPrior1YearInstant146000000JPY
Other nclCurrentQuarterInstant233000000JPY
Noncurrent liabilitiesPrior1YearInstant4208000000JPY
Noncurrent liabilitiesCurrentQuarterInstant3270000000JPY
LiabilitiesPrior1YearInstant7001000000JPY
LiabilitiesCurrentQuarterInstant6049000000JPY
Capital stockPrior1YearInstant1201000000JPY
Capital stockCurrentQuarterInstant2204000000JPY
Capital surplusPrior1YearInstant1642000000JPY
Capital surplusCurrentQuarterInstant2626000000JPY
Retained earningsPrior1YearInstant5239000000JPY
Retained earningsCurrentQuarterInstant4676000000JPY
Treasury stockPrior1YearInstant-348000000JPY
Treasury stockCurrentQuarterInstant-300000000JPY
Shareholders equityPrior1YearInstant7734000000JPY
Shareholders equityCurrentQuarterInstant9207000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant－JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant152000000JPY
Foreign currency translation adjustmentPrior1YearInstant309000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant401000000JPY
Valuation and translation adjustmentsPrior1YearInstant309000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant554000000JPY
Subscription rights to sharesPrior1YearInstant－JPY
Subscription rights to sharesCurrentQuarterInstant1000000JPY
Net assetsPrior1YearInstant8044000000JPY
Net assetsCurrentQuarterInstant9763000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass